◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Molecular Partners AG (MOLN) Financial History

Name: Molecular Partners AG (MOLN) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-08

Molecular Partners AG (MOLN) operates in the Biotechnology industry and is headquartered in Schlieren, Switzerland with about 134 employees. Its market capitalization is roughly $167 million. In the fiscal year ended 2025-12-31, MOLN reported CHF 0M in revenue and (CHF 62M) in net income.

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

Interactive charts & full statements →

MOLN Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CHF 0M	CHF 5M	CHF 7M	CHF 190M	—
Operating Income (EBIT)	(CHF 55M)	(CHF 61M)	(CHF 61M)	CHF 117M	—
Net Income	(CHF 62M)	(CHF 54M)	(CHF 62M)	CHF 118M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MOLN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	CHF 0M	CHF 0M	CHF 0M	CHF 0M	CHF 0M	—
Operating Income (EBIT)	(CHF 14M)	(CHF 13M)	(CHF 13M)	(CHF 12M)	(CHF 15M)	—
Net Income	(CHF 14M)	(CHF 13M)	(CHF 13M)	(CHF 12M)	(CHF 20M)	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MOLN Free Cash Flow History

MOLN Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 102M	CHF 158M	CHF 198M	CHF 262M	—
Total Liabilities	CHF 22M	CHF 17M	CHF 22M	CHF 27M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MOLN viewer.

Other Companies in Biotechnology

MDWD · MediWound Ltd. — $179 million
MENS · Jyong Biotech Ltd. — $171 million
CRBU · Caribou Biosciences, Inc. — $168 million
LENZ · LENZ Therapeutics, Inc. — $167 million
SPRB · Spruce Biosciences, Inc. — $166 million
CDXS · Codexis, Inc. — $160 million
HUMA · Humacyte, Inc. — $158 million
INDP · Indaptus Therapeutics, Inc. — $156 million

← MOLDTKPAC All “M” companies MOLOWVOL →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.